title: Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
abstract: OBJECTIVE
  To investigate the impact of adding rituximab to intensive chemotherapy with peripheral-blood progenitor cell (PBPC) autograft for high-risk diffuse large B-cell lymphoma (DLB-CL) and follicular lymphoma (FL).
  
  
  METHODS
  Data were collected from 10 centers associated with Gruppo Italiano Terapie Innnovative nei Linfomi for 522 patients with DLB-CL and 223 patients with FL (median age, 47 years) who received the original or a modified high-dose sequential (HDS) chemotherapy regimen. HDS was delivered to 396 patients without (R-) and to 349 patients with (R+) rituximab; 154 (39%) and 178 patients (51%) in the R- and R+ subsets, respectively, underwent HDS for relapsed/refractory disease.
  
  
  RESULTS
  A total of 355 R- (90%) and 309 R+ patients (88%) completed the final PBPC autograft. Early treatment-related mortality was 3.3% for R- and 2.8% for R+ (P = not significant). Two parameters significantly influenced the outcome: disease status at HDS, with 5-year overall survival (OS) projections of 69% versus 57% for diagnosis versus refractory/relapsed status, respectively, and rituximab addition, with 5-year OS of 69% versus 60% in the R+ versus R- groups, respectively. In the multivariate analysis, these two variables maintained an independent prognostic value. The marked benefit of rituximab was evident in patients receiving HDS as salvage treatment: the 5-year OS projections for R+ versus R- were, respectively, 64% versus 38%, for patients with refractory disease or early relapse and 71% versus 57%, for patients with late relapse, partial response, or second/third relapse.
  
  
  CONCLUSIONS
  The results of this large series indicate that rituximab should be included in the current practice of PBPC autograft for DLB-CL and FL.
authors.affiliation: Dipartimento Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Az. Osp. S. Giovanni Battista, Via Genova 3, 10126 Torino, Italy. corrado.tarella@unito.it
authors.forename: Corrado
authors.initials: C
authors.lastname: Tarella
authors.forename: Manuela
authors.initials: M
authors.lastname: Zanni
authors.forename: Michele
authors.initials: M
authors.lastname: Magni
authors.forename: Fabio
authors.initials: F
authors.lastname: Benedetti
authors.forename: Caterina
authors.initials: C
authors.lastname: Patti
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pileri
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
authors.forename: Fabio
authors.initials: F
authors.lastname: Ciceri
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Sergio
authors.initials: S
authors.lastname: Cortelazzo
authors.forename: Ignazio
authors.initials: I
authors.lastname: Majolino
authors.forename: Salvo
authors.initials: S
authors.lastname: Mirto
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
authors.forename: Roberto
authors.initials: R
authors.lastname: Passera
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Gianni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007558:Italy; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D002945:Cisplatin; D008558:Melphalan; D008727:Methotrexate